Search Results - "Koncz, Tamas"

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

“…In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and…”
Get full text

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis by van Vollenhoven, Ronald F, Fleischmann, Roy, Cohen, Stanley, Lee, Eun Bong, García Meijide, Juan A, Wagner, Sylke, Forejtova, Sarka, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wallenstein, Gene V, Krishnaswami, Sriram, Bradley, John D, Wilkinson, Bethanie

“…In this trial of patients with rheumatoid arthritis who were on stable doses of methotrexate, tofacitinib, a novel oral Janus kinase inhibitor, was more…”
Get full text

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial by Burmester, Gerd R, Prof, Blanco, Ricardo, MD, Charles-Schoeman, Christina, MD, Wollenhaupt, Jürgen, Prof, Zerbini, Cristiano, MD, Benda, Birgitta, MD, Gruben, David, PhD, Wallenstein, Gene, PhD, Krishnaswami, Sriram, PhD, Zwillich, Samuel H, MD, Koncz, Tamas, MD, Soma, Koshika, MD, Bradley, John, MD, Mebus, Charles, PhD

“…Summary Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently…”
Get full text

Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations by Hughes, Dyfrig, PhD, MSc, Cowell, Warren, MSc, BSc, Koncz, Tamas, MD, Cramer, Joyce, BS

“…Abstract Objectives Suboptimal compliance and failure to persist with drug treatments are important determinants of therapeutic nonresponse and are of…”
Get full text

Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study by Emery, Paul, MA, MD, FRCP, Koncz, Tamas, MD, Pan, Sharon, PhD, Lowry, Simon, MD

“…Abstract Background: The hip is the second most common large joint that is affected by osteoarthritis (OA), with prevalence ranging from 3% to 11% in patients…”
Get full text

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial by KREMER, Joel, LI, Zhan-Guo, ZWILLICH, Samuel H, KONCZ, Tamas, RIESE, Richard, BRADLEY, John, HALL, Stephen, FLEISCHMANN, Roy, GENOVESE, Mark, MARTIN-MOLA, Emilio, ISAACS, John D, GRUBEN, David, WALLENSTEIN, Gene, KRISHNASWAMI, Sriram

“…Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs). Tofacitinib is a…”
Get full text

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia by Guimarães, Patrícia O, Quirk, Daniel, Furtado, Remo H, Maia, Lilia N, Saraiva, José F, Antunes, Murillo O, Kalil Filho, Roberto, Junior, Vagner M, Soeiro, Alexandre M, Tognon, Alexandre P, Veiga, Viviane C, Martins, Priscilla A, Moia, Diogo D.F, Sampaio, Bruna S, Assis, Silvia R.L, Soares, Ronaldo V.P, Piano, Luciana P.A, Castilho, Kleber, Momesso, Roberta G.R.A.P, Monfardini, Frederico, Guimarães, Helio P, Ponce de Leon, Dario, Dulcine, Majori, Pinheiro, Marcia R.T, Gunay, Levent M, Deuring, J. Jasper, Rizzo, Luiz V, Koncz, Tamas, Berwanger, Otavio

“…Patients who were hospitalized with Covid-19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo…”
Get full text

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis by Strand, Vibeke, van Vollenhoven, Ronald F, Lee, Eun Bong, Fleischmann, Roy, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wilkinson, Bethanie, Wallenstein, Gene

“…To evaluate effects of tofacitinib or adalimumab on patient-reported outcomes (PROs) in patients with moderate to severe RA and inadequate responses to MTX. In…”
Get full text

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors by Rendas-Baum, Regina, Wallenstein, Gene V, Koncz, Tamas, Kosinski, Mark, Yang, Min, Bradley, John, Zwillich, Samuel H

“…The long-term treatment of rheumatoid arthritis (RA) most often involves a sequence of different therapies. The response to therapy, disease progression and…”
Get full text

Adherence to biologic DMARD therapies in rheumatoid arthritis by Koncz, Tamas, Pentek, Marta, Brodszky, Valentin, Ersek, Katalin, Orlewska, Ewa, Gulacsi, Laszlo

“…The efficacy of the biologic disease-modifying antirheumatic drugs (DMARDs) shown in clinical trials may be jeopardized due to prevalent poor patient…”
Get more information

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies by Fleischmann, Roy, Kremer, Joel, Tanaka, Yoshiya, Gruben, David, Kanik, Keith, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie, Zwillich, Samuel H., Keystone, Edward

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, the safety and efficacy data from five Phase 2 studies of…”
Get full text

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial by Strand, Vibeke, Lee, Eun Bong, Fleischmann, Roy, Alten, Rieke E, Koncz, Tamas, Zwillich, Samuel H, Gruben, David, Wilkinson, Bethanie, Krishnaswami, Sriram, Wallenstein, Gene

“…To compare patient-reported outcomes (PROs) in methotrexate (MTX)-naive patients (defined as no prior treatment or ≤3 doses) receiving tofacitinib versus MTX…”
Get full text

Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient's perspective by Rendas-Baum, Regina, Bayliss, Martha, Kosinski, Mark, Raju, Aditya, Zwillich, Samuel H., Wallenstein, Gene V., Koncz, Tamas

“…Abstract Objective: Health measurements used to evaluate the effectiveness of rheumatoid arthritis (RA) therapies often fail to reflect patients' priorities,…”
Get full text

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-[alpha] inhibitors by Rendas-Baum, Regina, Wallenstein, Gene V, Koncz, Tamas, Kosinski, Mark, Yang, Min, Bradley, John, Zwillich, Samuel H

“…Introduction The long-term treatment of rheumatoid arthritis (RA) most often involves a sequence of different therapies. The response to therapy, disease…”
Get full text

Statistical Comments Are Unfounded by Hughes, Dyfrig, Cowell, Warren, Koncz, Tamas, Cramer, Joyce

Get full text

Clinical and pharmacoeconomic impact of patient medication adherence by Koncz, Tamas

“…This thesis addresses what is considered to be an important, yet often neglected aspect of pharmacoeconomic analyses: patient adherence with pharmacotherapy…”
Get full text

Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization by Koncz, T. A., Lister, S. P., Makinson, G. T.

“…ABSTRACT Objective: To assess co-prescription of gastroprotective agents (GPAs) for non-selective NSAID (nsNSAID)-treated patients in UK primary care, and the…”
Get full text

medR: Software System for Managing Medical History and Patient Examination Data by Rethi, Anita-Bella, Antal, Krisztian-Tamas, Mathe, Orsolya, Foszto, Matyas, Koncz, Tamas, Simon, Karoly

“…The purpose of the medR project is to lighten the burden on the local healthcare system given by the sub-optimal handling of large amounts of information. The…”
Get full text

Economic evaluation of population-based mass screening for the early detection of cancer: a systematic review by Muszbek, Noémi, Koncz, Tamás, V Hajdú, Piroska, Adány, Róza

“…The increasing premature mortality due to cancer has made population based screening programs for cervical,breast and colorectal cancers inevitable in Hungary…”
Get more information